Published on : Feb 26, 2016
ALBANY, New York, Feb 26, 2016: Immune-mediated inflammatory diseases are common chronic ailments affecting almost 5% to 7% of Western populations. The symptoms and key patient demographics of these diseases are often disparate, yet they are pathophysiologically linked. These diseases share the common characteristic of occurring due to dysregulation of immune pathways, accompanied by inadequate immune response. Disease-modifying anti-rheumatic drugs in general are a highly genericized category of systematic small-molecule-based agents. These drugs are used in the first line treatment of immune-mediated inflammatory diseases. However, in most cases, they are supplemented by shorter-term glucocorticoid therapy.
The report, titled “Global Immunology Market to 2022 - Large pipeline and competitive market to drive long-term market growth,” recently added to the repertoire of ResearchMoz.us studies the existing therapies in immunology, and those that are in pipeline. It presents a comprehensive overview of the global immunology market and studies how it will get influenced by a plethora of market trends.
Click here to get more info with TOC in a PDF Format: https://www.researchmoz.us/enquiry.php?type=S&repid=536322
The existing treatment modalities often fail to elicit appropriate long-term response. This has paved the way for the second-line therapy segment to emerge in the market, beginning with the approval of Enbrel (etanercept) and Remicade (infliximab) in 1998. The segment includes monoclonal antibodies (mAbs). Premium systemic mAbs are already highly successful commercially due to their extensive usage and high cost. Despite the patent expiry of many of the existing mAbs and impending patent expiry of a few others, the global immunology market is anticipated to witness continued growth. Remicade and Humira (adalimumab) are among the commercially successful products due to lose their patent protection.
According to the report, the global immunology market, which stood at US$61.5 bn in 2015, will reach US$74.2 bn by 2022, exhibiting a CAGR of 2.71% therein.
The pharmaceutical pipeline of the global immunology market is very large, comprising over 1,838 in-development active products. However, these products are expected to exhibit moderate commercial performance in the late stage pipeline.
The report studies the widening gaps between patent expiry and pipeline products in the market and how they are addressed by late-stage pipeline pharmaceutical products. The impact of the looming patent expiry of blockbuster drugs on the overall market operations is also studied in detail in the report. To present a holistic overview, the report investigates how manufacturers of these blockbuster drugs, such as Johnson & Johnson and AbbVie, will respond to the situation.
The global immunology market is dominated by the leading 20 pharmaceutical companies. These companies are expected to maintain their lead in the market through the report’s forecast period. The profiles of these companies are included in the report. Using SWOT analysis, the report weighs out the strengths, weaknesses, opportunities, and threats that these companies will witness until 2022. Financial reports of these companies are also referred to for the purpose of the study.
With an aim to assist the market stakeholders in their future undertakings, the report provides an executive-level blueprint of the global immunology market. Exhaustive information compiled in the report includes aspects such as market definition, segmentation, and growth trajectory. Valuable insights from market experts are also included in the report to help existing enterprises as well as new entrants understand the market dynamics better.
To order report Call USA – Canada Toll Free: 866-997-4948 or send an email on firstname.lastname@example.org